Market capitalization | $2.59b |
Enterprise Value | $2.51b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 126.22 |
EV/Sales (TTM) EV/Sales | 4.58 |
P/S ratio (TTM) P/S ratio | 4.72 |
P/B ratio (TTM) P/B ratio | 6.09 |
Revenue growth (TTM) Revenue growth | 24.67% |
Revenue (TTM) Revenue | $547.47m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
16 Analysts have issued a Inari Medical Inc forecast:
16 Analysts have issued a Inari Medical Inc forecast:
Dec '23 | |
Current assets | 236 236 |
Fixed assets | 439 439 |
Total Assets | 674 674 |
Dec '23 | |
Equity | 465 465 |
Debt capital | 209 209 |
Total Capital | 674 674 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Head office | United States |
CEO | Andrew Hykes |
Employees | 1,300 |
Founded | 2011 |
Website | www.inarimedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.